Pharmacodynamic Models for Discrete Data
暂无分享,去创建一个
Michel Tod | Pascal Girard | P. Girard | G. Freyer | Gilles Freyer | M. Tod | Ines Paule | I. Paule
[1] Gordon Graham,et al. Determination of an Optimal Dosage Regimen Using a Bayesian Decision Analysis of Efficacy and Adverse Effect Data , 2002, Journal of Pharmacokinetics and Pharmacodynamics.
[2] R. Hamman,et al. Association between higher cumulative doses of recombinant erythropoietin and risk for retinopathy of prematurity. , 2006, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.
[3] Analysis of responses in migraine modelling using hidden Markov models , 2007, Statistics in medicine.
[4] K. Blesch,et al. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. , 2003, British journal of clinical pharmacology.
[5] Jerome J. Schentag,et al. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. , 1997, The Journal of antimicrobial chemotherapy.
[6] Siv Jönsson,et al. Estimating Bias in Population Parameters for Some Models for Repeated Measures Ordinal Data Using NONMEM and NLMIXED , 2004, Journal of Pharmacokinetics and Pharmacodynamics.
[7] Mats O Karlsson,et al. Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS. , 2004, British journal of clinical pharmacology.
[8] J Wakefield,et al. Cumulative logit models for ordinal data: a case study involving allergic rhinitis severity scores , 2001, Statistics in medicine.
[9] Patrick J. Johnson,et al. Modeling and Simulation of Sexual Activity Daily Diary Data of Patients with Female Sexual Arousal Disorder Treated with Sildenafil Citrate (Viagra®) , 2006, Pharmaceutical Research.
[10] D. Hedeker,et al. A Mixed-eeects Regression Model for Three-level Ordinal Response Data , 2022 .
[11] John Eose,et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trial , 2010, British Journal of Cancer.
[12] Mats O. Karlsson,et al. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080 , 2010, Journal of Pharmacokinetics and Pharmacodynamics.
[13] M. Danhof,et al. A model-based approach to treatment comparison in acute migraine. , 2006, British journal of clinical pharmacology.
[14] E. Snoeck,et al. Dose–response population analysis of levetiracetam add-on treatment in refractory epileptic patients with partial onset seizures , 2007, Epilepsy Research.
[15] Carmen Cadarso-Suárez,et al. Multi-state models for the analysis of time-to-event data , 2009, Statistical methods in medical research.
[16] Lewis B. Sheiner,et al. A Population Pharmacokinetic–Pharmacodynamic Analysis of Repeated Measures Time-to-Event Pharmacodynamic Responses: The Antiemetic Effect of Ondansetron , 1999, Journal of Pharmacokinetics and Biopharmaceutics.
[17] D R Stanski,et al. Population pharmacodynamic model for ketorolac analgesia , 1996, Clinical pharmacology and therapeutics.
[18] Meindert Danhof,et al. A pharmacodynamic Markov mixed‐effect model for the effect of temazepam on sleep , 2000, Clinical pharmacology and therapeutics.
[19] L B Sheiner,et al. Quantitative characterization of therapeutic index: Application of mixed‐effects modeling to evaluate oxybutynin dose–efficacy and dose–side effect relationships , 1999, Clinical pharmacology and therapeutics.
[20] Andrew C. Hooker,et al. Modeling Subpopulations with the $MIXTURE Subroutine in NONMEM: Finding the Individual Probability of Belonging to a Subpopulation for the Use in Model Analysis and Improved Decision Making , 2009, The AAPS Journal.
[21] J. Hagenaars,et al. Methods in Human Growth Research: Ordinal longitudinal data analysis , 2004 .
[22] Brian Corrigan,et al. Exposure‐response analysis of pregabalin add‐on treatment of patients with refractory partial seizures , 2003, Clinical pharmacology and therapeutics.
[23] J. Verweij,et al. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea , 2002, Clinical pharmacology and therapeutics.
[24] J. Lindsey,et al. Simple models for repeated ordinal responses with an application to a seasonal rhinitis clinical trial. , 1997, Statistics in medicine.
[25] Naoki Ishiguro,et al. A MULTICENTRE STUDY , 2010 .
[26] L. Aarons,et al. Methodological approaches to the population analysis of toxicity data. , 2001, Toxicology letters.
[27] C. Veyrat‐Follet,et al. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization , 2000, Clinical pharmacology and therapeutics.
[28] A. Agresti,et al. Multinomial logit random effects models , 2001 .
[29] Pascal Girard,et al. Empirical Bayes estimation of random effects of a mixed-effects proportional odds Markov model for ordinal data , 2011, Comput. Methods Programs Biomed..
[30] Modeling and Simulation to Support Dose Selection and Clinical Development of SC‐75416, a Selective COX‐2 Inhibitor for the Treatment of Acute and Chronic Pain , 2008, Clinical pharmacology and therapeutics.
[31] Lynn McFadyen,et al. A Two-Part Mixture Model for Longitudinal Adverse Event Severity Data , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[32] M. Barras,et al. Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events. , 2009, British journal of clinical pharmacology.
[33] L E Friberg,et al. A Pharmacodynamic Markov Mixed‐Effects Model for Determining the Effect of Exposure to Certolizumab Pegol on the ACR20 Score in Patients With Rheumatoid Arthritis , 2009, Clinical pharmacology and therapeutics.
[34] Mats O. Karlsson,et al. Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models , 2011, Pharmaceutical Research.
[35] Evaluation of Mixture Modeling with Count Data Using NONMEM , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[36] W. Weber,et al. Lessons learned from a phase III population pharmacokinetic study of cariporide in coronary artery bypass graft surgery , 2002, Clinical pharmacology and therapeutics.
[37] L B Sheiner,et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. , 1980, Clinical pharmacology and therapeutics.
[38] I. Court-Fortune,et al. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. , 2008, Lung cancer.
[39] L B Sheiner,et al. A Markov mixed effect regression model for drug compliance. , 1998, Statistics in medicine.
[40] G. Demetri,et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis , 2010, Cancer Chemotherapy and Pharmacology.
[41] Elisa Lee,et al. Statistical Methods for Survival Data Analysis: Lee/Survival Data Analysis , 2003 .
[42] P. Girard,et al. Exposure-Effect Population Model of Inolimomab, a Monoclonal Antibody Administered in First-Line Treatment for Acute Graft-Versus-Host Disease , 2007, Clinical pharmacokinetics.
[43] F. Harrell,et al. Partial Proportional Odds Models for Ordinal Response Variables , 1990 .
[44] D. Mould,et al. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors , 2002, Clinical pharmacology and therapeutics.
[45] A. Megens,et al. Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[46] Adrian Dunne,et al. Analysis of Nonrandomly Censored Ordered Categorical Longitudinal Data from Analgesic Trials , 1997 .
[47] Matts Kågedal,et al. Modelling a Spontaneously Reported Side Effect by Use of a Markov Mixed-Effects Model , 2005, Journal of Pharmacokinetics and Pharmacodynamics.
[48] L B Sheiner,et al. A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data , 1994, Clinical pharmacology and therapeutics.
[49] Mark E. Sale,et al. A Joint Model for Nonlinear Longitudinal Data with Informative Dropout , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[51] C. Twelves,et al. A Dynamic Model of Hand‐and‐Foot Syndrome in Patients Receiving Capecitabine , 2009, Clinical pharmacology and therapeutics.
[52] Chuanpu Hu,et al. Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure–response modeling of physician’s global assessment score for ustekinumab in patients with psoriasis , 2011, Journal of Pharmacokinetics and Pharmacodynamics.
[53] I. Trocóniz,et al. Population Pharmacokinetic/Pharmacodynamic Modelling of the Analgesic Effects of Tramadol in Pediatrics , 2006, Pharmaceutical Research.
[54] R. Miller,et al. Exposure‐response Analysis for Spontaneously Reported Dizziness in Pregabalin‐treated Patient With Generalized Anxiety Disorder , 2008, Clinical pharmacology and therapeutics.
[55] M. Hutmacher,et al. Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients , 2008, Journal of Pharmacokinetics and Pharmacodynamics.
[56] Mats O. Karlsson,et al. Modelling overdispersion and Markovian features in count data , 2009, Journal of Pharmacokinetics and Pharmacodynamics.
[57] A. Agresti,et al. The analysis of ordered categorical data: An overview and a survey of recent developments , 2005 .
[58] P. Girard,et al. Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation , 2012, Cancer Chemotherapy and Pharmacology.
[59] L. Aarons,et al. Sample Size/Power Calculations for Population Pharmacodynamic Experiments Involving Repeated-Count Measurements , 2009, Journal of biopharmaceutical statistics.
[60] P. McCullagh. Regression Models for Ordinal Data , 1980 .
[61] J. Anderson,et al. Regression, Discrimination and Measurement Models for Ordered Categorical Variables , 1981 .
[62] P. Marcellin,et al. Pharmacokinetic/Pharmacodynamic and Time-to-Event Models of Ribavirin-Induced Anaemia in Chronic Hepatitis C , 2005, Clinical pharmacokinetics.
[63] A. Agresti. Modelling ordered categorical data: recent advances and future challenges. , 1999, Statistics in medicine.
[64] J. DeJongh,et al. Population pharmacokinetic and pharmacodynamic modeling of propofol for long‐term sedation in critically ill patients: A comparison between propofol 6% and propofol 1% , 2002, Clinical pharmacology and therapeutics.
[65] F. Raffi,et al. Indinavir Trough Concentration as a Determinant of Early Nephrolithiasis in HIV-1-Infected Adults , 2007, Therapeutic drug monitoring.
[66] J J Schentag,et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients , 1993, Antimicrobial Agents and Chemotherapy.